VativoRx, LLC

06/17/2026

FDA approved Bizengri® for NRG1 fusion-positive cholangiocarcinoma, the first approved therapy for this rare bile duct cancer subset. It already covers NSCLC and pancreatic cancer with the same fusion. Biomarker-driven oncology keeps expanding.

https://vativorx.com/pharmacy-bulletin-06-17-2026/

On May 8, 2026, the US Food and Drug Administration (FDA) approved a new indication for Partner Therapeutics’ Bizengri® (zenocutuzumab‑zbco) for adults who have advanced, unresectable, or metastatic cholangiocarcinoma harboring a neuregulin-1 (NRG1) gene fusion with disease progression on or af...

06/16/2026

FDA granted accelerated approval to Beqalzi™ (sonrotoclax) for relapsed/refractory mantle cell lymphoma after BTK inhibitor failure, a new oral BCL-2 inhibitor for a rare, aggressive cancer with limited options post-BTK.

https://vativorx.com/pharmacy-bulletin-06-16-2026/

On May 13, 2026, the US Food and Drug Administration (FDA) granted accelerated approval to BeOne Medicines’ Beqalzi™ (sonrotoclax) for the treatment of adult patients who have relapsed or refractory (R/R) mantle cell lymphoma (MCL) and have received at least two prior lines of therapy, including...

06/12/2026

FDA approved Langlara™ as an interchangeable biosimilar to Lantus® (insulin glargine), meaning pharmacists can substitute it without a new prescription. More competition, more access for insulin-dependent patients.

https://vativorx.com/pharmacy-bulletin-06-12-2026/

On April 29, 2026, the US Food and Drug Administration (FDA) approved a new interchangeable biosimilar to Sanofi’s Lantus® (insulin glargine) called Langlara™ (insulin glargine-aldy – Sunshine Lake Pharma/Lanexa Biologics) for the treatment of adults and pediatric patients who have type 1 dia...

06/09/2026

FDA approved Veppanu™, the first oral PROTAC therapy for ESR1-mutated ER+/HER2- metastatic breast cancer. A new class of drug that fully degrades the estrogen receptor rather than just blocking it. Approved a month ahead of schedule.

https://vativorx.com/pharmacy-bulletin-06-09-2026

The US Food and Drug Administration (FDA) has approved Veppanu™ (vepdegestrant – Arvinas, Inc.), an proteolysis‑targeting chimera (PROTAC) therapy, on May 1, 2026 for the treatment of adults who have estrogen receptor‑positive, human epidermal growth factor receptor 2‑negative (ER+/HER2‑...

06/03/2026

FDA approved a self-injectable version of Saphnelo® for lupus. Patients can now administer it at home weekly via autoinjector — no longer limited to IV infusions in a clinical setting. A meaningful convenience win for SLE management.

https://vativorx.com/pharmacy-bulletin-06-03-2026/

On April 24, 2026, the US Food and Drug Administration (FDA) approved AstraZeneca’s Saphnelo® (anifrolumab‑fnia) for subcutaneous (SC) self‑administration as a once‑weekly autoinjector for the treatment of adult patients who have moderate to severe systemic lupus erythematosus (SLE).

05/29/2026

PSG's 2026 data shows 1 in 5 organizations cannot track their actual specialty drug net cost inclusive of rebates and discounts.

For those who can — the follow-on question is whether the medical benefit layer is actually in that number.

New edition of The Rebate Report looks at what goes into net drug cost, where gaps typically appear, and why it matters more in 2026 than it did before. 👇

📋https://www.linkedin.com/pulse/specialty-drug-net-cost-number-how-confident-you-whats-inside-yndbe

05/28/2026

FDA expanded Stelara® (ustekinumab) for Crohn's disease in kids as young as 2. The IL-12/IL-23 inhibitor has been a mainstay in adult IBD, now younger pediatric patients have access to the same established therapy.

https://vativorx.com/pharmacy-bulletin-05-28-2026/

On April 15, 2026, the US Food and Drug Administration approved an expanded indication for Johnson & Johnson Innovation Medicine’s Stelara® (ustekinumab) for the treatment of moderately to severely active Crohn’s disease in pediatric patients aged two years and older.

05/22/2026

FDA approved Idvynso™, a once-daily, 2-drug HIV tablet from Merck. It's the first maintenance regimen for virologically suppressed adults that doesn't include an integrase inhibitor. Available in pharmacies after May 11.

https://vativorx.com/pharmacy-bulletin-05-22-2026/

On April 20, 2026, the US Food and Drug Administration (FDA) approved Merck’s Idvynso™ (doravirine/islatravir – Merck) for the treatment of Human Immunodeficiency Virus-1 (HIV) infection in adults who are virologically suppressed.

05/21/2026

FDA expanded Vabysmo® (faricimab) for retinal vein occlusion beyond six months, removing a label barrier that forced treatment switches in patients still responding well. Cleaner long-term management for a common cause of vision loss.

https://vativorx.com/pharmacy-bulletin-05-20-2026/

On April 9, 2026, the US Food and Drug Administration (FDA) approved Genentech’s, a member of the Roche Group, Vabysmo® (faricimab‑svoa), an intravitreal injectable bispecific antibody, for the treatment of macular edema due to retinal vein occlusion (RVO) beyond six months in adults.

05/19/2026

Generic dapagliflozin (Farxiga®) is here. FDA approved multiple AB-rated generics for this $10B+ SGLT2 inhibitor used in heart failure, CKD, and type 2 diabetes. Significant cost relief expected for patients and payers alike.

https://vativorx.com/pharmacy-bulletin-05-19-2026/

On April 7, 2026, the US Food and Drug Administration (FDA) approved several manufacturers’ AB-rated generics to AstraZeneca’s Farxiga® (dapagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor.